Cognition Therapeutics to Participate in Next-Generation Alzheimer’s Disease Panel at Virtual Biotech Showcase on January 11, 2022
Lisa Ricciardi, CEO, to participate as a Panelist in, “Aduhelm: Stimulating the Next- Generation of AD Treatment”
PURCHASE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, today announced that Lisa Ricciardi, president and CEO of Cognition Therapeutics, will participate in a Biotech Showcase panel discussion, entitled, “Aduhelm: Stimulating the Next Generation of AD Treatment.”
This virtual panel, discussing the shift in Alzheimer’s disease investment sentiment, is scheduled to take place on Tuesday, January 11th from 8:00 to 9:00 a.m. PT. Joining Ms. Ricciardi in the discussion will be CEOs of five companies committed to research and innovation in neurodegenerative diseases.
Details of the panel discussion are as follows:
|Panel:||Aduhelm: Stimulating the Next Generation of AD Treatment|
|Date:||January 11, 2022|
|Time:||8:00 – 9:00 a.m. PT|
The event will be livestreamed and available for replay by registered attendees. Registration details may be found here: https://informaconnect.com/biotech-showcase/registration-options/.
During Biotech Showcase, members of Cognition’s management team will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies.
Cognition's proprietary lead product candidate, CT1812, is an orally delivered, small molecule designed to penetrate the blood-brain barrier and bind selectively to the σ-2 receptor complex, a key multiprotein regulator of cellular processes that are disrupted in Alzheimer’s and other degenerative diseases. CT1812 is currently in Phase 2 clinical development and has been granted FDA Fast Track designation in Alzheimer’s disease and is covered by composition-of-matter patents through 2035.
About Cognition Therapeutics:
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. For more information, visit https://cogrx.com.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and are available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Cognition Therapeutics, Inc.
Aline Sherwood (media)
Lisa Sher (investors)
Tiberend Strategic Advisors, Inc.